Pharmaron Beijing Co., Ltd.

HKSE 3759.HK

Pharmaron Beijing Co., Ltd. Net Income for the year ending December 31, 2023: USD 225.51 M

Pharmaron Beijing Co., Ltd. Net Income is USD 225.51 M for the year ending December 31, 2023, a 13.21% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.
  • Pharmaron Beijing Co., Ltd. Net Income for the year ending December 31, 2022 was USD 199.19 M, a -23.80% change year over year.
  • Pharmaron Beijing Co., Ltd. Net Income for the year ending December 31, 2021 was USD 261.41 M, a 45.55% change year over year.
  • Pharmaron Beijing Co., Ltd. Net Income for the year ending December 31, 2020 was USD 179.61 M, a 128.58% change year over year.
  • Pharmaron Beijing Co., Ltd. Net Income for the year ending December 31, 2019 was USD 78.58 M, a 59.31% change year over year.
Key data
Date Net Income EPS (Diluted) Shares (Diluted, Weighted) Net Income Margin
Market news
Loading...
HKSE: 3759.HK

Pharmaron Beijing Co., Ltd.

CEO Dr. Boliang Lou Ph.D.
IPO Date Nov. 28, 2019
Location China
Headquarters 6 Taihe Road
Employees 20,295
Sector Health Care
Industries
Description

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Similar companies

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 2.14

2.31%

2359.HK

WuXi AppTec Co., Ltd.

USD 6.95

4.11%

3347.HK

Hangzhou Tigermed Consulting Co., Ltd.

USD 3.72

2.09%

1801.HK

Innovent Biologics, Inc.

USD 4.45

2.34%

9926.HK

Akeso, Inc.

USD 7.28

2.32%

StockViz Staff

January 15, 2025

Any question? Send us an email